Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort

Annals of Medicine

Volumn 46, Issue 3, 2014, Pages 155-162

  Funke Kaiser, Anne ^a   Havulinna, Aki S ^b   Zeller, Tanja ^a   Appelbaum, Sebastian ^a   Jousilahti, Pekka ^b   Vartiainen, Erkki ^b   Blankenberg, Stefan ^a   Sydow, Karsten ^a   Salomaa, Veikko ^b  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

BiomarCaRE; Biomarkers; Cardiovascular disease; Heart failure; Midregional pro adrenomedullin; Natriuretic peptides; Risk factor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; PROADRENOMEDULLIN; TROPONIN I; ADRENOMEDULLIN; NATRIURETIC FACTOR; PROTEIN PRECURSOR;

ADULT; ADVERSE OUTCOME; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DEATH; FEMALE; FINLAND; HEART FAILURE; HEART INFARCTION; HUMAN; IMMUNOASSAY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; AGED; BLOOD; COMPARATIVE STUDY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED;

ADRENOMEDULLIN; ADULT; AGED; C-REACTIVE PROTEIN; FEMALE; FINLAND; HEART FAILURE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS;

EID: 84899798859     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.874662     Document Type: Article

References (36)

1. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007; 14(Suppl 2): S1-113.
2. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002; 106: 388-91.
3. Koenig W. Update on integrated biomarkers for assessment of longterm risk of cardiovascular complications in initially healthy subjects and patients with manifest atherosclerosis. Ann Med. 2009; 41: 332-43.
4. Romanens M, Ackermann F, Spence JD, Darioli R, Rodondi N, Corti R, et al. Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. Eur J Cardiovasc Prev Rehabil. 2010; 17: 18-23.
5. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and infl ammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002; 105: 2632-7.
6. Mora S, Rifai N, Buring JE, Ridker PM. Additive value of immunoassaymeasured fi brinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006; 114: 381-7.
7. Lowe GD, Sweetnam PM, Yarnell JW, Rumley A, Rumley C, Bainton D, et al. C-reactive protein, fi brin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Th romb Vasc Biol. 2004; 24: 1957-62.
8. de Lemos J A, Drazner M H, Omland T, Ayers C R, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010; 304: 2503-12.
9. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008; 358: 2107-16.
10. van Hateren KJ, Alkhalaf A, Kleefstra N, Groenier KH, de Jong PE, de Zeeuw D, et al. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. Clin Chem. 2012; 58: 293-7.
11. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004; 350: 655-63.
12. McKie PM, Cataliotti A, Sangaralingham SJ, Ichiki T, Cannone V, Bailey KR, et al. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc. 2011; 86: 1154-60.
13. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993; 192: 553-60.
14. Kitamura K, Kangawa K, Kojima M, Ichiki Y, Matsuo H, Eto T. Complete amino acid sequence of porcine adrenomedullin and cloning of cDNA encoding its precursor. FEBS Lett. 1994; 338: 306-10.
15. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005; 51: 1823-9.
16. Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech. 2002; 57: 3-13.
17. Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K, et al. Hemodynamic Effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol. 1993; 241: 271-3.
18. Kobayashi K, Kitamura K, Hirayama N, Date H, Kashiwagi T, Ikushima I, et al. Increased plasma adrenomedullin in acute myocardial infarction . Am Heart J. 1996; 131: 676-80.
19. Kobayashi K, Kitamura K, Etoh T, Nagatomo Y, Takenaga M, Ishikawa T, et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J. 1996; 131: 994-8.
20. Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, et al. Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratifi cation of patients with acute dyspnea: an observational study. Crit Care. 2009; 13: R122.
21. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005; 9: R816-24.
22. Potocki M, Breidthardt T, Reichlin T, Hartwiger S, Morgenthaler NG, Bergmann A, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med. 2010; 267: 119-29.
23. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSIheart failure (GISSI-HF) trial. Eur J Heart Fail. 2010; 12: 338-47.
24. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, et al. Comparative evaluation of B-type natriuretic peptide, midregional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007; 13: 42-9.
25. Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin Chem. 2012; 58: 226-36.
26. Neumann JT, Tzikas S, Funke-Kaiser A, Wilde S, Appelbaum S, Keller T, et al. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis. 2013; 228: 451-9.
27. Brouwers FP, de Boer RA, van der Harst P, Struck J, de Jong PE, de Zeeuw D, et al. Infl uence of age on the prognostic value of midregional pro-adrenomedullin in the general population. Heart. 2012; 98: 1348-53.
28. Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Mannisto S, Sundvall J, et al. Th irty-fi ve-year trends in cardiovascular risk factors in Finland. Int J Epidemiol. 2010; 39: 504-18.
29. Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005; 12: 132-7.
30. Mahonen M, Jula A, Harald K, Antikainen R, Tuomilehto J, Zeller T, et al. The validity of heart failure diagnoses obtained from administrative registers. Eur J Prev Cardiol. 2013; 20: 254-9.
31. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010; 121: 2388-97.
32. Pencina MJ, D ' Agostino RB Sr, D ' Agostino RB J r, V asan R S. E valuating the added predictive ability of a new marker: from area under the ROC curve to reclassifi cation and beyond. Stat Med. 2008; 27: 157-72; discussion 207-12.
33. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem. 2008; 54: 17-23.
34. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011; 30: 377-99.
35. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fi brillation. J Am Coll Cardiol. 2010; 56: 1712-19.
36. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009; 302: 49-57.